27 February 2024 | Tuesday | News
Fujifilm Irvin Technology is a leader in the innovation and manufacturing of cell culture solutions in the global life sciences and medical markets. With the approval of the company's three products - embryo culture solution (CSCM-C), embryo culture oil and sperm freeze solution by the State Drug Administration (NMPA), the company today announced the expansion of its assisted reproductive technology (ART) product portfolio in China. These new products represent the main market growth opportunities in the region in response to the growing demand for professional technical support related to the company's full range of medium solutions and in vitro fertilization (IVF) workflow.
These three products are sold through Fujifilm (China) Investment Co., Ltd.
Previously, Fujifilm Irven Technology only provided a small number of products in China for in vitro fertilization (IVF) male and gamete and embryo treatment solution. Recently, the approval of the National Drug Administration (NMPA) has enabled the company's product portfolio in China to expand to the field of embryonic media and meet the changing needs of customers in the assisted reproductive market at every step of the IVF process.
• CSCM-C embryonic culture solution is a new solution, an uninterrupted culture system specially designed for the 5th and 6th days of in vitro fertilization (IVF). CSCM-C medium has proved its success as an industry-leading one-step medium and has been applied worldwide. The medium provides optimized embryonic culture conditions without the need to replace the culture dish or the culture solution, providing a high-quality, low-cost and labor-efficient solution for embryonic development. The company makes a monthly production plan for culture solution, aiming to continuously provide fresh culture solution to end users.
• Embryo culture oil is a sterile, lightweight mineral oil designed to protect small-volume culture solution. The oil is used as a covering layer during the culture process, which provides a physical barrier for embryonic development, effectively prevents evaporation, and protects the culture solution from changes in osmotic pressure and pH, which may affect the survival rate of the embryo.
• Arctic sperm freeze solution is an optimized cryopreservation solution used to support the freezing and thawing of sperm cells in in vitro fertilization, and improves the male product portfolio of Fujifilm Owen Technology in China. The cryophilic preservation solution is a unique formula of double buffer solution without test yolk buffer (TYB), which can work efficiently in a low ratio of 3:1 between semen and freezer. Compared with the most commonly used cryoste, the amount of Arctic sperm freeze required for a single application is reduced by up to 60%, thus significantly reducing the cost of freeze and consumables. The freeze contains antioxidants and key amino acids - designed to effectively maintain semen function and DNA integrity. In addition, the dual buffer system of HEPES and MOPS can maintain a stable environment on the console, extend the shelf life and reduce storage costs.
Steven Geimer, executive director of the medical business department of Fujifilm Irvine Scientific, said: "We are very happy to see that these three products with successful performance in the global market have been approved for sale in China. These new products further expand our product lineup in China, enabling customers to access a more complete portfolio of high-quality assisted reproductive technology solutions, including our industry-leading one-step embryo culture solution.
Mr. Suzuki Minehiko, General Manager of the Life Science Division of Fujifilm (China) Investment Co., Ltd., said: "Since 1986, Fujifilm Owen Technology has been committed to the innovative development of new products to reduce embryo pressure, achieve consistent results, and improve the survival rate of oocytes and embryos. As we take the next step to solve the challenges in the field of in vitro fertilization, we are committed to helping patients realize the dream of having a family, which is an exciting time.
© 2024 Biopharma Boardroom. All Rights Reserved.